_

#999999; border-top-color: #999999; border-bottom: #999999 1px solid; border-right-color: #999999" width="90%"> SUNESIS PHARMAC. DL-,0001

Übersicht     Kurse     Charts     News     Forum

#666666; background-color: #f0f0f0" align="left">ISIN: US8673285024   Symbol: SNSS Einfügen in: Watchlist | Depot

 

Intraday   5 Tage   3 Monate   1 Jahr   3 Jahre   Gesamt   Diskussionen  mehr... >>   Bew.   Ant.   Titel Autor Zeit  Neues Thema

__________________________________________________ "Malo mori quam foederari - Lieber sterben als sich entehren"

.

Hat lange gedauert bis dieser Wert interessant wurde...aber heute war es soweit.

Biotec und Pharma haben gewaltigen Aufholbedarf...

Auch in Deutschland schlummern noch einige Perlen im Abseits...warten darauf wachgeküsst zu werden.

Wer schlau ist schaut genauer hin.

 

Nasdaq USA

de.advfn.com/...chart&s=N^SNSS&p=0&t=16&vol=1" style="max-width:560px" />

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sunesis Pharma, wer investieren will sollte einen Rücksetzer abwarten!

Fällt  MORGEN weit unter 1,00 $

 

lala

StockPreacher Initiates Independent Research Coverage for Sunesis Pharmaceuticals Inc.


Jan 8, 2010 6:50:00 AM

2010 GlobeNewswire, Inc.

DALLAS, Jan. 8, 2010 (GLOBE NEWSWIRE) -- StockPreacher.com announces an investment report featuring Sunesis Pharmaceuticals Inc. (Nasdaq:SNSS). The report includes financial and investment analysis, analyst consensus, and pertinent industry information you need to know to make an educated investment decision.

The full report is available at: www.stockpreacher.com/n/SNSS

ADVERTISEMENTView More Ads | Disclaimer   Related Quotes

Last Change % Change
SNSS 1.4099  
0.0899  6.81  



Get our alerts BEFORE the rest of the market. Follow us on Twitter: twitter.com/StockPreacher

Sunesis Pharmaceuticals Inc. (SNSS), a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for hematologic and solid tumor cancers. The Company has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. Voreloxin is currently being evaluated as a single agent in a phase 2 clinical trial in platinum-resistant ovarian cancer, in a phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly acute myeoloid leukemia (AML) patients unlikely to benefit from standard induction chemotherapy and in a phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. SNSS has formed strategic research and drug discovery partnerships with leading pharmaceutical and biopharmaceutical companies, including Biogen Idec Inc.and SARcode Corp.

Message Board Search for SNSS: www.boardcentral.com/boards/SNSS

In the report, the analyst notes:

"SNSS focuses on the development of voreloxin, a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Seeing voreloxin's favorable competitive profile, SNSS has built a highly experienced cancer drug development organization committed to advancing its lead product candidate.

"In December, SNSS presented positive phase 2 clinical data of voreloxin in AML at the American Society of Hematology 2009 Annual Meeting, which highlighted voreloxin's strong efficacy and safety profile when used as a single agent or in combination with chemotherapy in patients with difficult to treat AML. 'These results provide us with the efficacy and safety data to move voreloxin forward into pivotal testing,' Steven Ketchum Ph.D., SNSS senior vice president of Research and Development, said in a company press release."

To read the entire report visit: www.stockpreacher.com/n/SNSS

StockPreacher.com is a small-cap research and investment commentary provider. StockPreacher.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on StockPreacher, please visit: www.stockpreacher.com

StockPreacher.com Disclosure

StockPreacher.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. StockPreacher.com is a Web site wholly-owned by BlueWave Advisors, LLC. Please read our report and visit our Web site, StockPreacher.com, for complete risks and disclosures.

CONTACT: StockPreacher.com
       Nic Lesmeister
       (469)-252-3505
       info@stockpreacher.com

gibts irgendweleche kursziele? bzw. Analysen. Oder muß ich auf Highmaster warten;-)

DAUSEND ;-)

Gruss
-cubiak

Hier mal ein Bericht von vor 3 Jahren vom "Der Aktionär"

Hier war noch die Phase I , jetzt sind am Ende der Phase 2 !

Also kann die Party bald losgehen !  

Die Experten von Global Biotech Investing schreiben, dass sieben von insgesamt acht Analysten die Papiere von Sunesis Pharmaceuticals (WKN A0DP2J) mit einem Kursziel von durchschnittlich neun US-Dollar zum Kauf empfehlen würden. Das 132-Millionen-Dollar-Unternehmen erforscht den Wirkstoff „SNS-595“ gegen kleinzellige und nicht-kleinzellige Tumoren sowie gegen Leukämie. Anfang Dezember meldete die Firma vielversprechende Daten einer Phase-I-Studie bei traditionell therapie-resistenten Leukämiefällen. Analysten schätzen, dass Sunesis noch im ersten Halbjahr die Ergebnisse verschiedener Phase-II-Studien präsentieren und eine ganze Reihe neuer Studien beginnen wird. Überdies bewerten die Analysten von Needham das Management als bemerkenswert stark besetzt, wie auch die Aktionärsliste. Das Investmenthaus Warburg Pincus hält 12,4 Prozent, Biogen-Idec knapp zehn Prozent, zwei institutionelle Investoren weitere elf Prozent und Bristol Myers fast 4,5 Prozent. Nun scheinen auch einige Investmentfonds auf das Unternehmen aufmerksam geworden zu sein..





www.deraktionaer.de/xist4c/web/...CB00666682D40707E8A6ADF04D0C

Voreloxin, alone and in combination with cytarabine, was evaluated in 3 human acute leukemia cell lines: HL-60 (acute promyelocytic leukemia), MV4-11 (AML with a FLT3 mutation) and CCRF-CEM (acute lymphoblastic leukemia). Voreloxin was active in all the leukemia cell lines, including the AML cell line, which is relatively resistant to cytarabine in vitro. Using a combination index (CI) analysis, voreloxin with cytarabine demonstrated synergistic cytotoxic activity HL-60 and MV4-11 cells, and additive activity in CCRF-CEM cells.

In a series of elegant in vivo studies, a murine model of bone marrow ablation was used to evaluate the activity of voreloxin and cytarabine alone and in combination. Bone marrow cellularity, peripheral white blood cell and platelet counts were monitored to assess the impact of and recovery from the study treatments. Voreloxin alone or in combination with cytarabine caused reversible bone marrow ablation accompanied by profound reductions in peripheral white blood cells that were reversible within one week, consistent with the therapeutic goals of AML treatment. The activity of voreloxin at maximum tolerated dose (MTD) was superior to cytarabine at MTD. In addition, the combination demonstrated supra-additive activity in vivo, with a substantially enhanced, but fully reversible, reduction in bone marrow cellularity as compared to each agent alone.

The Cancer Chemotherapy and Pharmacology article and full, published data set are available online at www.springerlink.com/content/n7577n7281832171/.

About Voreloxin

Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML, as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that nearly 13,000 new cases of AML will be diagnosed and approximately 9,000 deaths from AML will occur in the U.S. in 2009. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit www.sunesis.com. SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

This press release contains forward-looking statements, including without limitation statements related to voreloxin's efficacy, safety profile and effects as a single agent and in combination with other AML treatments in both clinical and nonclinical studies, voreloxin's mechanism of action and results that may warrant further clinical evaluation of voreloxin. Words such as "demonstrate," "enhanced," "contribute," "translate," "active," "caused," "demonstrated" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include without limitation, the risk that Sunesis' drug development activities for voreloxin could be halted or significantly delayed for various reasons, the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' nonclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials, risks related to the manufacturing of voreloxin, and the risk that Sunesis' proprietary rights may not adequately protect voreloxin. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investor and Media Inquiries:
Andrea Rabney
Argot Partners
212-600-1902

Eric Bjerkholt
Sunesis Pharmaceuticals, Inc.
650-266-3717


SOURCE: Sunesis

The Phase 1b/2 trial is designed to evaluate the safety, pharmacokinetics and anti-leukemic activity of escalating doses of voreloxin when administered on days one and four with cytarabine, given either as a continuous infusion of 400 mg/m2 daily for five days or as a two hour IV bolus of 1 g/m2 daily for five days. A recommended pivotal dose-regimen of voreloxin used in combination with cytarabine has been identified based on results of the Phase 1b/2 clinical trial to date.

About Voreloxin

Voreloxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis. Voreloxin is currently being evaluated in a fully enrolled single agent Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a fully enrolled Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. A Phase 2 single agent trial in platinum-resistant ovarian cancer has also completed enrollment. Sunesis expects to begin Phase 3 testing in AML later in 2010.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that nearly 13,000 new cases of AML will be diagnosed and approximately 9,000 deaths from AML will occur in the U.S. in 2009. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. AML patients with relapsed or refractory disease and newly diagnosed AML patients over 60 years of age with poor prognostic risk factors typically die within one year, resulting in an acute need for new treatment options for these patients.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to advancing its lead product candidate, voreloxin, in multiple indications to improve the lives of people with cancer. For additional information on Sunesis Pharmaceuticals, please visit www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

This press release contains forward-looking statements, including without limitation statements related to voreloxin's efficacy and safety profile both as a single agent and in combination with other AML treatments in clinical studies, voreloxin's mechanism of action, results that may warrant further clinical evaluation of voreloxin and the timing of Phase 3 studies of voreloxin in AML. Words such as "plan," "encouraged," "believe," "expects" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include without limitation, the risk that Sunesis' drug development activities for voreloxin could be halted or significantly delayed for various reasons, the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the risk that preliminary data and trends may not be predictive of future data or results, the risk that Sunesis' nonclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies, risks related to the conduct of Sunesis' clinical trials, risks related to the manufacturing of voreloxin, and the risk that Sunesis' proprietary rights may not adequately protect voreloxin. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investor and Media Inquiries:
Andrea Rabney
Argot Partners
212-600-1902

Eric Bjerkholt
Sunesis Pharmaceuticals Inc.
650-266-3717

Sunesis Pharmaceuticals buy
12.02.2010 - 17:09

Rating-Update:

New York (aktiencheck.de AG) - Die Analysten von Jefferies & Co stufen die Aktie von Sunesis Pharmaceuticals (ISIN US8673285024/ WKN A0DP2J) weiterhin mit "buy" ein. Das Kursziel werde von 1,50 USD auf 2 USD erhöht. (12.02.2010/ac/a/u) Analyse-Datum: 12.02.2010


Quelle: Finanzen.net

Denke am Montag gibt es Gewinnmitnahmen. Hoffe nur das der Kurs nicht allzustark abfällt.

What Hedge Fund Managers Are Doing Before Dawn

Hedge Fonds-Manager Nr. 3: Spezialisiert auf kleine Biotechs.

"Meine Position als Nummer eins bei weitem Sunesis Pharmaceuticals (SNSS)," erzählte er mir. SNSS macht Vorolexin, ein Medikament zur Behandlung von AML Leukämie. Phase-II-Ergebnisse zeigten, dass sie die Überlebensfähigkeit von AML-Patienten erhöht.

Hedge Fonds-Manager Nr. 3 hat mir drei atalysts auf SNSS:

"1). 1Q10 regulatorische Änderung am Voreloxin von der FDA
2.) Mehrere Präsentationen auf der ASCO Jahrestagung, Anzeigen Voreloxin in reifen Datensätzen, einschließlich der Kombination Cytarabin Daten
3) Abschluss eines Partner für ph. III-Tests bei AML.
Ich erwarte, dass dies zu einem $ 3 - $ 5 hat in wenigen Monaten sein ", schloss er.

http://blogs.wsj.com/financial-adviser/2010/03/26/...ing-before-dawn/

http://www.emailwire.com/release/...ABIO-SNSS-GENZ-AEN-ARIA-DNDN.html

Genau deshalb schwankte der Kurs zw. 0,76-1,05 USD. Denke am Montag gibt es heftige Gewinnmitnahmen. Hoffe nur das der Kurs nicht allzustark abfällt.

Dies soll keine Handelsaufforderung darstellen.Nur Meine Meinung.

sunpharma.com/admin/news/upload/631.pdf

Sun Pharmaceutical

Sollte wieder steigen, es ist bald ASCO !

files.shareholder.com/downloads/SUNP/...orate_Presentation.pdf

07.06.2010 21:04
www.finanznachrichten.de/...sed-or-refractory-patients-256.htm

Sunesis Announces Data From Phase 2 Clinical Program of Voreloxin in Acute Myeloid Leukemia Support Phase 3 Trial in Relapsed or Refractory Patients / Updated, Positive Phase 2 Data in AML and Ovarian Cancer Presented at the ASCO 2010 Annual Meeting;


...weiter siehe LINK

Ich glaube hier ist was im Busch, warum kaufen soviele Insider Ihre eigene Aktie. Doch nur wenn Sie daran glauben und was wissen !!!
www.bloggingstocks.com/2010/07/13/...is-unify-corp-and-others/

Sunesis Issued European Patent Covering Voreloxin Combination

Date : 07/15/2010 @ 8:00AM
Source : MarketWire
Stock : Sunesis Pharmaceuticals, Inc. (SNSS)

ih.advfn.com/...pid=nmona&article=43614381&symbol=SNSS

Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the European Patent Office (EPO) has granted a European patent covering combinations of the Company's lead drug candidate, voreloxin, with cytarabine. Cytarabine is the standard-of-care treatment for Acute Myeloid Leukemia (AML), and the therapy used in combination with voreloxin in a fully enrolled Phase 2 trial in patients with relapsed and/or refractory AML. Sunesis has also announced plans to initiate a multinational, randomized, double-blind, placebo-controlled, pivotal Phase 3 clinical trial of voreloxin in combination with cytarabine in a relapsed/refractory AML patient population in the second half of this year. European Patent No. 1 729 770 B1, titled "SNS-595 [voreloxin] and Methods of Using the Same," following completion of the patent validation process, will provide patent coverage for such combination products in 30 member states of the European Patent Convention, including the major European markets, through 2025. Corresponding patent applications are pending in major markets throughout the world including Australia, Canada, Japan and the United States.

"This patent is an important new addition to our intellectual property estate, as it covers the combination of voreloxin and cytarabine, the contemplated initial market application," stated Daniel Swisher, Chief Executive Officer of Sunesis. "We are pursuing a sophisticated and deliberate strategy to provide exclusive coverage in the voreloxin patent estate out to 2030. Beyond our granted patents, we have filed patent applications covering formulations, combination uses, dosing, manufacturing processes and composition of matter claims. We look forward to the successful prosecution of these patent applications in multiple territories around the world."

...(weiter siehe LINK)

erst bei 2.01 in hohen stückzahlen abverkauft, nun wieder in noch höheren stückzahlen zu 0.28$ eingekauft.

bei dem titel passiert was!?

Sunesis Launches Phase 3 VALOR Trial of Vosaroxin in AML

Date : 12/21/2010 @ 8:00AM
Source : MarketWire
Stock : Sunesis Pharmaceuticals (SNSS)

ih.advfn.com/p.php?pid=nmona&article=45739543

unesis Pharmaceuticals, Inc. (NASDAQ: SNSS) today announced that the first patient has been randomized and dosed with blinded study treatment in its pivotal Phase 3 VALOR trial of vosaroxin, the company's lead drug candidate, in combination with cytarabine in patients with first relapsed or refractory acute myeloid leukemia (AML). The VALOR trial is a multinational, randomized, double-blind, placebo-controlled, pivotal trial which is expected to enroll 450 evaluable patients at leading sites in the U.S., Canada, Europe, Australia and New Zealand.

"The initiation of VALOR marks the culmination of many years of work and is a gratifying moment for Sunesis in its ongoing efforts to develop a new therapeutic option for AML patients," stated Daniel Swisher, Chief Executive Officer of Sunesis. "AML is a challenging disease, especially for relapsed and refractory patients, yet in our robust Phase 2 program we have shown in this AML setting that vosaroxin plus a leading standard of care, cytarabine, exhibit a combination of efficacy and tolerability that has led to promising results. The support of key opinion leaders, top international trial sites, specialized service providers and a rigorously designed Phase 3 protocol should provide the VALOR trial with a strong foundation for operational success."

"Patients with relapsed or refractory AML have a poor prognosis and are often intolerant of or do not respond to currently available treatment options," said Farhad Ravandi, M.D., Associate Professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, and a principal investigator of VALOR. "Despite the unmet medical need, treatment standards have not appreciably changed in more than 30 years. Vosaroxin's differentiated treatment profile from the Phase 2 program is characterized by strong remission rates, low all-cause early mortality and long leukemia free survival, which have led to survival outcomes that compare favorably with published results for current treatment standards. The VALOR trial is a well designed, highly anticipated trial which should provide a clear understanding of vosaroxin's efficacy and safety profile when added to cytarabine in this disease setting."

Patients in the VALOR trial will be randomized one-to-one to receive in a blinded manner either vosaroxin or placebo on days one and four of each treatment cycle in combination with cytarabine daily for five days of each treatment cycle. The trial's primary endpoint is overall survival. The VALOR trial employs an adaptive design that provides for a single interim analysis by an independent Data and Safety Monitoring Board (DSMB) which will meet to examine pre-specified efficacy and safety data sets and decide whether to implement a one-time sample size adjustment of 225 additional evaluable patients to maintain adequate power across a broad range of clinically meaningful and statistically significant survival outcomes. The interim analysis by the DSMB is expected to take place in mid-2012. For more information on VALOR please visit www.valortrial.com.

RBC Capital Markets - Sunesis Pharmaceuticals "outperform"

16:46 20.12.10
http://www.ariva.de/news/...ls-outperform-RBC-Capital-Markets-3609274

Rating-Update:

Toronto (aktiencheck.de AG) - Die Analysten von RBC Capital Markets stufen die Aktie von Sunesis Pharmaceuticals (Profil) von "sector perform" auf "outperform" hoch. Das Kursziel werde von 2 USD auf 1 USD gesenkt. (20.12.2010/ac/a/u)

realtime.bigcharts.com/...tyle=2003&size=1&mocktick=1" style="max-width:560px" alt="" />

finance.yahoo.com/q?s=SNSS
www.finanznachrichten.de/...aktien/sunesis-pharmaceuticals.asp

bin ja seit jahren mehr auf wallstreet online unterwegs...
aber in jeder aktie, die ich seit 1 woche im biotech bereich hier auf ariva
"abgrase" finde ich dich...muss dich auf meine watchlist setzen -
du scheinst ein echt gutes "gespür" zu haben...!!!

bin nach Repros Th. gestern abend zu $ 0,53 hier rein...AH sehr stark!

we will see!

ih.advfn.com/p.php?pid=squote&symbol=SNSS

der vorstand hat heute schon verdoppelt! kz: 2,-$

anstieg hoffentlich mit guten nachrichten! suche schon mal

ir.sunesis.com/...ol-newsArticle&ID=1678333&highlight=

Sunesis and Royalty Pharma Announce $25 Million Vosaroxin Royalty Agreement
Design and Execution of VALOR Trial Enable Innovative Financing

SOUTH SAN FRANCISCO, Calif., March 29, 2012 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals (Nasdaq:SNSS) and Royalty Pharma today announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development of Sunesis' lead product candidate vosaroxin, to acquire a royalty on future worldwide net sales of vosaroxin.

Image: Sunesis Pharmaceuticals, Inc. Logo


Image: Royalty Pharma Logo

Sunesis is evaluating vosaroxin in a pivotal Phase 3, randomized, double-blind, placebo-controlled trial, the VALOR trial, in patients with first relapsed or refractory acute myeloid leukemia (AML). The VALOR trial employs an adaptive trial design that permits a one-time increase in sample size at the interim analysis by its Data and Safety Monitoring Board (DSMB). At the interim analysis, expected in the third quarter of 2012, the DSMB will examine pre-specified efficacy and safety data sets and decide whether to stop the study early for efficacy or futility, continue the study as planned or implement a one-time sample size adjustment of 225 additional evaluable patients.

Under terms of the agreement, Royalty Pharma will invest $25 million immediately following VALOR's interim analysis if: (a) the study stops early for efficacy, in exchange for a 3.6% participation payment on future net sales; or (b) the one-time sample size increase is being implemented, in exchange for a 6.75% participation payment on future net sales as well as two warrants. In the case when VALOR proceeds to its planned 450 patient enrollment, Royalty Pharma has the option to make a $25 million investment upon the unblinding of the study in exchange for a 3.6% participation payment on future net sales. The warrants issued to Royalty Pharma are exercisable if VALOR's sample size is increased and are each to purchase 1,000,000 shares of Sunesis common stock at an exercise price of $3.48 and $4.64 per share, respectively. Sunesis currently holds all worldwide commercial rights to its vosaroxin product.

"Royalty Pharma has a strong track record of identifying significant commercial opportunities in the pharmaceutical sector. We believe this commitment by Royalty Pharma is a validation of vosaroxin's potential in AML and reflects the significant upside of a positive VALOR trial," stated Daniel Swisher, Chief Executive Officer of Sunesis.

"This innovative transaction will provide us with access to added capital that extends our runway beyond the unblinding of VALOR and enables our team to actively prepare for vosaroxin's regulatory filings and US commercial launch. It will also allow us to selectively expand our development program and enhance our strategic flexibility on the timing and terms of vosaroxin partnering arrangements outside the US," added Eric Bjerkholt, Executive Vice President, Corporate Development & Finance of Sunesis.

"Sunesis' use of an adaptive trial design offers us an opportunity to invest in this promising biopharmaceutical product candidate on terms that are a win-win for both Sunesis and Royalty Pharma: Sunesis gains access to a flexible, novel financing structure and we are able to invest in vosaroxin at a time when we believe its likelihood of commercial success will be high," said Pablo Legorreta, Chief Executive Officer of Royalty Pharma. "Based on our extensive due diligence, we are impressed with the Sunesis team, the robust preclinical and clinical dataset for vosaroxin, as well as the rigor of the VALOR trial design and implementation. We are pleased to be partnering with Sunesis in this transaction, and believe that this first-in-class compound has the potential to transform the treatment landscape for AML and potentially other cancers."

About VALOR

VALOR is a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial in patients with first relapsed or refractory AML. The trial is expected to enroll 450 evaluable patients at more than 110 leading sites in the U.S., Canada, Europe, Australia and New Zealand. The VALOR trial is currently enrolling patients, who are randomized one to one to receive either vosaroxin on days one and four in combination with cytarabine daily for five days, or placebo in combination with cytarabine. Additionally, the VALOR trial employs an innovative, adaptive trial design that allows for a one-time sample size adjustment by the DSMB at the interim analysis to maintain adequate power across a broader range of survival outcomes. The trial's primary endpoint is overall survival. For more information on the VALOR trial, please visit www.valortrial.com.

About Vosaroxin

Vosaroxin is a first-in-class anti-cancer quinolone derivative (AQD), a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, G2 arrest and apoptosis..............................

für alle auf eine grüne Woche.

erst wenn ichs sehe, trotzdem.... : ))

http://www.ariva.de/news/...steinschaetzung-Cantor-Fitzgerald-4071364

Cantor Fitzgerald - Sunesis Pharmaceuticals-Aktie: Ersteinschätzung

08:13 16.04.12

New York (www.aktiencheck.de) - Die Analysten von Cantor Fitzgerald stufen die Aktie von Sunesis Pharmaceuticals (SUNESIS PHARMACEUTICALS Aktie) in einer Ersteinschätzung mit dem Rating "buy" ein. Das Kursziel sehe man bei 6,00 USD. (Analyse vom 13.04.2012) (16.04.2012/ac/a/a)

Offenlegung von möglichen Interessenskonflikten: Mögliche Interessenskonflikte können Sie auf der Site des Erstellers/ der Quelle der Analyse einsehen.

Denn lass dich mal positiv in der nächsten Zeit überraschen, die die Veröffentlichung der Phase 3 Daten kommt immer näher...
Kurse um 4,5 - 5,5 $ werden im Vorfeld voraussichtlich erreicht, wenn man sich mal vergleichbare Firmen/Medikament anschaut...

Mal gucken, was heute bekannt gegeben wird...

wohl noch ein bischen. Wann ungefähr kommen denn die Daten von Phase 3.
Weiß das jemand?

and almost ready to go

an den Phase 3 Daten liegt?

Es wurde doch nichts neues veröffentlicht - oder habe ich gepennt?

auf den yahoo boards weiß keiner etwas, ich erwarte die Daten heute in der Vorbörse gegen 13.30Uhr, mal schauen.

ich habe so ein Spielchen schon öfters bei Bios gesehen, hier wollen noch ein paar große Ju
ngs rein...

VALOR is a Phase 3, randomized, double-blind, placebo-controlled, pivotal trial of vosaroxin in patients with first relapsed or refractory AML. The pre-planned sample size increase of 225 additional patients is designed to maintain adequate statistical power over a broader range of survival outcomes. With the revised target sample size of 675 patients, Sunesis anticipates full enrollment of VALOR in 2013, with unblinding of the trial expected in the first half of 2014 upon reaching 562 events and final database lock. The DSMB recommendation also triggers Royalty Pharma's obligation to invest $25.0 million in Sunesis.

"The completion of VALOR's interim analysis is an important milestone for Sunesis," said Daniel Swisher, Chief Executive Officer of Sunesis. "In light of the design of VALOR, the DSMB's recommendation that we implement a one-time, 225-patient sample size increase is a promising development. We thank the DSMB for their comprehensive analysis, and trial investigators for their continued support of VALOR, which has now enrolled 412 patients. Importantly, we are pleased that we have committed funding that will allow us to implement this enrollment expansion and complete the pivotal trial in AML."

Sunesis' management and staff, VALOR clinical investigators, including members of the Study Steering Committee, and Royalty Pharma remain blinded to the interim trial data and analysis.

Royalty Pharma's $25.0 million investment is made pursuant to the terms of an agreement with Sunesis announced March 29, 2012. In exchange for their investment, Royalty Pharma will receive a 6.75% royalty on future net sales of vosaroxin and warrants to purchase Sunesis common stock.

Mich wundert es trotzdem sehr dass hier nicht mehr passiert.

Sind diese News nicht wirklich richtig positive?

Gibt es hier ein paar gedanken eurer seits???

 

Vielen Dank.

www.pazzosognofinanza.com/...fici&op=dettaglio&id=5649

Kommt hier ein Rebound? Was meint ihr?

Was meint Ihr?

Im dezember gabs nen price target 2,3$ von roth capital,nun 4 monate später auf 4,3 erhöht.

iwan

Capital Partners, LLC hat das Kursziel für Sunesis Pharmaceuticals Inc. von 430 auf 4 USD gesenkt, aber die Einstufung auf "Buy" belassen.

globenewswire.com/news-release/2015/06/12/...fvtc=2&fvtv=1

Sunesis Pharmaceuticals, Inc. has added a news release to its Investor Relations website.

Title: Sunesis Announces Publication of Vosaroxin Phase 3 VALOR Trial Results in The Lancet Oncology

Date(s): 4-Aug-2015 4:03 PM

For a complete listing of our news releases, please click here

SOUTH SAN FRANCISCO, Aug. 4, 2015 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that results from the Company's Phase 3 VALOR trial of vosaroxin and cytarabine in 711 patients with relapsed or refractory acute myeloid leukemia (AML) were published in the The Lancet Oncology. The VALOR results were first announced by the company on October 6, 2014. The article, titled "Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study" is available online first at www.thelancet.com/journals/lanonc/article/...)00201-6/abstract and will appear in the September 2015 print issue of The Lancet Oncology.

stockcharts.com/h-sc/ui?s=SNSS

www.nasdaq.com/de/symbol/snss/real-time

SNSS www.marketwatch.com/story/...s-of-vosaroxin-2016-08-25-7184046  

Sunesis meldet Zahlen für 2018

• Umsätze 0,2 Mio. $
  
• Verluste 27 Mio. $
  
• Cash 14 Mio. $
  
• MK 44 Mio. $
  

ir.sunesis.com/news-releases/...ourth-quarter-and-full-year-12

loooool

ja richtig!!lol

Die Kursentwicklung war absehbar, siehe #58.

Zahlen für Q3/19

• keine Umsätze
  
• Verlust 6 Mio. $
  
• Cash 38 Mio. $
  
• MK 26 Mio. $
  

ir.sunesis.com/news-releases/...s-third-quarter-2019-financial

unautorisierte Veröffentlichung ... bin hier auch auf dem falschen Fuß erwischt worden. Hatte sich angebahnt, aber wohl ohne Grund ... was für ein Volumen und was für ein Absturz ...

hier die Infos zur Posterpräsentation der ASH am Wochenende:

Shares: 111.32 Mill.
►LOSS 24 Mill
Low:$0,1951
High: $0,37925 -21:35 (MEZ)
Buy: $0,20
Sell: 0,36
Vol.: 150K
Tendenzy: down
Grottenschlechter Wert -
das interessiert Zocker-Kapitalisten nicht.

Zahlen für Q4/19

• Umsatz 2 Mio. $
  
• Verlust 5 Mio. $
  
• Cash 35 Mio. $
  
• MK 70 Mio. $
  

MK immer noch doppelt so hoch wie der Cashbestand, da bekomme ich andere Biotechs zum oder unter Cashwert.

ir.sunesis.com/news-releases/...ourth-quarter-and-full-year-13

die nächsten news positiv sind, dann sehen wir hier auch locker 1$ und mehr

Zahlen für Q1/20

• Umsatz 0,1 Mio. $
  
• Verlust 5,8 Mio. $
  
• Cash 29 Mio. $
  
• MK 66 Mio. $
  

ir.sunesis.com/news-releases/...s-first-quarter-2020-financial

Vecabrutinib wird nicht in die Phase2 Studie überführt

• Keine ausreichende Hinweise auf Aktivität
  
• MK 41 Mio. $
  

ir.sunesis.com/news-releases/...s-clinical-update-vecabrutinib

seekingalpha.com/news/...a-plunges-45-on-vecabrutinib-setback

12 Mio. $ Offering

• ~52 Mio. neue Aktien zu je 0,23$
  

ir.sunesis.com/news-releases/...-million-offering-common-stock

Ist an den Buyout-Gerüchten etwas dran? In den Staaten macht sich ja schon ein Zockerhype breit. Aber außer wenigen Indizien und Mutmaßungen liegt nix auf dem Tisch.  

Heute 1/10 RS

ir.sunesis.com/news-releases/...unces-1-10-reverse-stock-split

old.nasdaq.com/de/symbol/snss/real-time

Man stelle sich vor jemand , Namen darf man ja hier nicht nennen, empfehlt nach langer Vorankündigung um 19:25 Uhr die Aktie zu kaufen und die Lemminge kaufen brav.
Wahnsinn, dass das immer und immer wieder funktioniert.

schon wahnsinn, der Fisch. Werden nachher wieder 100 %, garantiert. Wir werden sehen :)

dass vor einigen Tagen immer geschrieben wurde, dass Kaufkurse erreicht werden, sobald wir unter 1,29 Dollar liegen. Aber jeder ist hier frei dabei, zu enscheiden, was er tut.  

man wie peinlich das Dummgepushe im  Chat ist, da beklatscht man vorbörsliche plus 10% bei 6000 Stück. Die man wahrscheinlich selbst gekauft hat. Naja das Schneeballsystem funktioniert für den Oberlemming immer.

das diesen kriminellen dummpushern nicht hinter schwedischen Gardinen kommen.  

runter zur Eröffnung nach der dummen Pusherei im pre market den ganzen morgen mit
50 postings vom Raubfisch  

wer es noch nicht gemerkt? manche brauchen Lemminge umd Geld zu verdienen und dazu eine Pusherseite    

seit vielen Jahren immer das Gleiche Spielchen  

1,13 Tradegate im PRE  jetzt 1,02  aktuell  

wie blöd solche Lemminge sind unglaublich , fallen auf jeden Müll rein der so geschrieben wird

"Tagesgewinner"    ??   NEIN  es fehlen fast 10 %  zum Tageshoch  

siehe HAI bei  CATB   Ansage ?    #1189  nur - 75 %   seit der """"""Ansage""""""

https://www.ariva.de/forum/...aktie-verdient-ein-forum-549362?page=47

Was für eine Rakete——-tja wer da heute für 1,1 gekauft hat——der glaubt nicht nur an Fische

Die Aktie von SNSS hat seit dem RS im September schonwieder 30% an Wert verloren.

Hallo Taubfisch...0,99 wie kann das sein ?

genauso eine Totgeburt wie Catabasis. Finger weg!!

mal wieder ein Dauerpush vom Raubfisch

- vor news
- profi buys
- jeder weiß wo die Aktie bald stehen wird
- Shorties halten die Aktie unten
- Bid mega
-  Mann Mann Mann

10 % tiefer wie letze Woche beim anderen Pushversuch 1,135 damals Tageshoch im Pre in D.

heute  bid nur 0,995 TDG  TT   und jetzt  

ich lese snss immer weiter ?   also bitte, der Raubfisch mal wieder

performance 1 Monat - 15 %

performance 3 Monate - 60 %  

heute + 1 %    die ganzen Märkte steigen extrem und dann kommt jemand mit so was daher

"buyer dran"  " immer weiter "      es sollte dem allerletzten klar sein was da so läuft oder ?

hier ist der Ofen offensichtlich aus

droht hier

die Märkte  und auch der Biotech Bereich explodieren   ist dieser  " mega "  "Tipp""

mal wieder nahe am Allzeit TIEF  

ja wer sich auf solche "Tipps"   verlässt dem ist nicht mehr zu helfen oder doch?

so wie bei jedem Titel, mal funktioniert es, mal nicht. Wenn aber jemand über so viel Kapital verfügt, lohnen sich die 2 - 3 Prozent bei entsprechenden Einsatz immer, vor allen Dingen, wenn man den ganzen Tag vor dem PC sitzt und tradet.

Und wenn dann eine Communiity mit 1.000 Teilnehmern auf dich hört, alle mindestens 6stellig unterwegs, kann ein Kurs schnell mal um 3 % anspringen.

Aber wichtig, keiner wird gezwungen, jeder drückt selber auf dem Knopf. Ich bin gespannt, ob wir dieses Jahr noch erheblich bessere Kurse sehen, nächste Woche sind zumindest News zu erwarten, wenn ich richtig informiert bin.

schau dir nur einmal die traurige Performance an. Hier läuft gar nichts mehr, ausser die Tränendrüsen der geleimten Jüngern eines Raubfisches

das war - und wird - wohl nix

Push Push Push  ... immer weiter ... immer weiter ...seit Tagen

Absturz  !!  - 10 %      ===>   Raubfisch  " null shares "

Leute nochmals :  lasst euch doch nicht ver....

Läuft doch.

www.globenewswire.com/news-release/2020/11/...r-Agreement.html

old.nasdaq.com/de/symbol/snss/real-time

Merger mit Viracta Therapeutics

ir.sunesis.com/news-releases/...viracta-therapeutics-announce

Russisches Roulette  

hab mir mal 1k zugelegt.

gute News:
seekingalpha.com/news/...eed_news_all&utm_medium=referral

und
Sunesis Pharmaceuticals Inc. and merger partner, Viracta Therapeutics Inc. announced that the U.S. Patent and Trademark Office has potentially issued a Notice of Allowance for patent application No. 16/924,082. Check the disclaimer on the landing page. Meanwhile, these other companies appear to be possibly providing nutritional supplements and medical devices. Do these markets catch your interests too? Here’s more interesting information: b.link/BillionWorthMedicalGreensPotentialPowerHouse

www.prnewswire.com/news-releases/...-placement-301234939.html

Reverse Split 1/3.5   upon completion of merge.
Looks like it’ll be trading under VIRX beginning tomorrow? (25.2.21)

D.h. der Kurs müsste mal 3.5 gerechnet werden und die Aktienzahl dividiert durch 3.5
Es ist auch noch unklar, unter welchem Begriff die zusammengeführte Firma kotiert sein wird.
Leider bin ich ev. etwas vorschnell rein, schauen wir mal heute.

(VIRX)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist

Quote Lookup

18.62+18.62 (+undefined)
At close: February 24 4:00PM EST
17.55 -1.07 (-5.75%)
Pre-Market: 8:29AM EST

Vorbörese positiv

20.00 +1.38 (7.41%)
Pre-Market: 9:01AM EST

dass wir Viracta erst am Montag in D handeln können.
stocktwits.com/symbol/VIRX

haben wir den Preis wie vor dem Resplit. Denkbar ungünstiger Tag für die Aktion.

Viracta Therapeutics (VIRX) PT Raised to $36 at Oppenheimer

bleibe ich mal, erfolgreiche Aussichten mit einem "wenn" versehen.

If Janssen decides to exclusively license VXRT's technology on a worldwide basis for its oral influenza vaccine, it could cause a BIG stock price jump. As of 3/4/21, Janssen STILL states that it's working on an oral influenza vaccine with Vaxart

www.jnj.com/innovation/...ge-how-we-prevent-and-treat-the-flu

Vorbörse
6.17 +0.25 (4.22%)
Pre-Market: 4:25AM EST

Es war keine Empfehlung damals sondern, erst mal zum Beobachten gedacht.

Wie es momentan steht, kann ich nicht beurteilen . Konnte den Wert nicht weiter verfolgen.

Verkaufen nützt nichts mehr, Verlust lieber aussitzen, wäre meine Strategie,.!
Und den Wert weiter beobachten.

Er heißt ja nun(VIRX).